Logo image of ITCI

INTRA-CELLULAR THERAPIES INC (ITCI) Stock Fundamental Analysis

USA - NASDAQ:ITCI - US46116X1019 - Common Stock

131.87 USD
-0.05 (-0.04%)
Last: 4/1/2025, 8:00:02 PM
131.92 USD
+0.05 (+0.04%)
After Hours: 4/1/2025, 8:00:02 PM
Fundamental Rating

5

ITCI gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ITCI as it has an excellent financial health rating, but there are worries on the profitability. ITCI is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ITCI has reported negative net income.
ITCI had a negative operating cash flow in the past year.
ITCI had negative earnings in each of the past 5 years.
In the past 5 years ITCI always reported negative operating cash flow.
ITCI Yearly Net Income VS EBIT VS OCF VS FCFITCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of ITCI (-5.46%) is better than 73.37% of its industry peers.
Looking at the Return On Equity, with a value of -6.50%, ITCI is in the better half of the industry, outperforming 78.39% of the companies in the same industry.
Industry RankSector Rank
ROA -5.46%
ROE -6.5%
ROIC N/A
ROA(3y)-19.53%
ROA(5y)-29.65%
ROE(3y)-23.06%
ROE(5y)-34.34%
ROIC(3y)N/A
ROIC(5y)N/A
ITCI Yearly ROA, ROE, ROICITCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

ITCI has a Gross Margin of 91.63%. This is amongst the best in the industry. ITCI outperforms 94.97% of its industry peers.
ITCI's Gross Margin has been stable in the last couple of years.
ITCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5YN/A
ITCI Yearly Profit, Operating, Gross MarginsITCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

8

2. Health

2.1 Basic Checks

ITCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ITCI has been increased compared to 1 year ago.
ITCI has more shares outstanding than it did 5 years ago.
ITCI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ITCI Yearly Shares OutstandingITCI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ITCI Yearly Total Debt VS Total AssetsITCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ITCI has an Altman-Z score of 38.03. This indicates that ITCI is financially healthy and has little risk of bankruptcy at the moment.
ITCI has a Altman-Z score of 38.03. This is amongst the best in the industry. ITCI outperforms 97.49% of its industry peers.
ITCI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 38.03
ROIC/WACCN/A
WACC9.49%
ITCI Yearly LT Debt VS Equity VS FCFITCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

ITCI has a Current Ratio of 6.36. This indicates that ITCI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.36, ITCI is in the better half of the industry, outperforming 76.38% of the companies in the same industry.
ITCI has a Quick Ratio of 6.23. This indicates that ITCI is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ITCI (6.23) is better than 76.88% of its industry peers.
Industry RankSector Rank
Current Ratio 6.36
Quick Ratio 6.23
ITCI Yearly Current Assets VS Current LiabilitesITCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.00% over the past year.
Looking at the last year, ITCI shows a very strong growth in Revenue. The Revenue has grown by 46.61%.
The Revenue has been growing by 484.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
Revenue 1Y (TTM)46.61%
Revenue growth 3Y101.03%
Revenue growth 5Y484.27%
Sales Q2Q%50.81%

3.2 Future

ITCI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 87.04% yearly.
ITCI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.51% yearly.
EPS Next Y127.35%
EPS Next 2Y174.17%
EPS Next 3Y140.69%
EPS Next 5Y87.04%
Revenue Next Year40.33%
Revenue Next 2Y50.81%
Revenue Next 3Y47.62%
Revenue Next 5Y37.51%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ITCI Yearly Revenue VS EstimatesITCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
ITCI Yearly EPS VS EstimatesITCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ITCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 660.59, which means the current valuation is very expensive for ITCI.
Based on the Price/Forward Earnings ratio, ITCI is valued a bit cheaper than 73.37% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.29. ITCI is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 660.59
ITCI Price Earnings VS Forward Price EarningsITCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400 600

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ITCI Per share dataITCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ITCI's earnings are expected to grow with 140.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y174.17%
EPS Next 3Y140.69%

More info and screens

0

5. Dividend

5.1 Amount

ITCI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTRA-CELLULAR THERAPIES INC

NASDAQ:ITCI (4/1/2025, 8:00:02 PM)

After market: 131.92 +0.05 (+0.04%)

131.87

-0.05 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-21 2025-02-21/bmo
Earnings (Next)05-05 2025-05-05/bmo
Inst Owners94.75%
Inst Owner Change-93.9%
Ins Owners0.23%
Ins Owner Change-26.06%
Market Cap14.05B
Analysts72.22
Price Target133.21 (1.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.8%
Min EPS beat(2)-40.63%
Max EPS beat(2)-24.97%
EPS beat(4)2
Avg EPS beat(4)0.62%
Min EPS beat(4)-40.63%
Max EPS beat(4)50.59%
EPS beat(8)6
Avg EPS beat(8)17.95%
EPS beat(12)9
Avg EPS beat(12)16.57%
EPS beat(16)10
Avg EPS beat(16)13.07%
Revenue beat(2)1
Avg Revenue beat(2)0.38%
Min Revenue beat(2)-0.24%
Max Revenue beat(2)1%
Revenue beat(4)3
Avg Revenue beat(4)0.36%
Min Revenue beat(4)-0.24%
Max Revenue beat(4)1%
Revenue beat(8)6
Avg Revenue beat(8)0.51%
Revenue beat(12)9
Avg Revenue beat(12)1.93%
Revenue beat(16)11
Avg Revenue beat(16)1.25%
PT rev (1m)-0.1%
PT rev (3m)26.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.86%
EPS NY rev (1m)-30.48%
EPS NY rev (3m)-47.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.15%
Revenue NY rev (1m)0.91%
Revenue NY rev (3m)1.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 660.59
P/S 20.63
P/FCF N/A
P/OCF N/A
P/B 12.23
P/tB 12.23
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)0.2
Fwd EY0.15%
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS6.39
BVpS10.78
TBVpS10.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.46%
ROE -6.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.63%
FCFM N/A
ROA(3y)-19.53%
ROA(5y)-29.65%
ROE(3y)-23.06%
ROE(5y)-34.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5YN/A
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 63.39%
Cap/Sales 0.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.36
Quick Ratio 6.23
Altman-Z 38.03
F-Score4
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)77.5%
Cap/Depr(5y)69.14%
Cap/Sales(3y)0.14%
Cap/Sales(5y)0.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
EPS Next Y127.35%
EPS Next 2Y174.17%
EPS Next 3Y140.69%
EPS Next 5Y87.04%
Revenue 1Y (TTM)46.61%
Revenue growth 3Y101.03%
Revenue growth 5Y484.27%
Sales Q2Q%50.81%
Revenue Next Year40.33%
Revenue Next 2Y50.81%
Revenue Next 3Y47.62%
Revenue Next 5Y37.51%
EBIT growth 1Y26.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year126.61%
EBIT Next 3Y133.69%
EBIT Next 5Y90.06%
FCF growth 1Y40.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.08%
OCF growth 3YN/A
OCF growth 5YN/A